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Background: Allergic rhinoconjunctivitis (ARC) due to birch pollen is a growing health concern in Europe. Here, we
report the efficacy and safety of 300IR birch pollen sublingual solution administered discontinuously for 2
consecutive years to patients with birch-associated allergic rhinoconjunctivitis.
Methods: Birch pollen-allergic adults were randomized in this double blind study to 300IR birch pollen sublingual
solution or placebo, daily, starting 4 months before and continuing through the pollen season for two pollen
seasons. Randomization was stratified according to the presence or absence of oral allergy syndrome (OAS). The
primary efficacy endpoint was the Average Adjusted Symptom Score (AAdSS) over the second pollen season and
was analyzed by ANCOVA. Secondary efficacy endpoints included the AAdSS over the first pollen period. Safety was
evaluated by means of adverse event monitoring.
Results: 574 patients (284 in the active group and 290 in the placebo group) were randomized and 496 completed
the study. Over the second pollen period, the least square (LS) mean AAdSS was significantly lower in the 300IR
group than in the placebo group (LS mean difference −2.04, 95% CI [−2.69, −1.40], (p <0.0001) with a relative
reduction of 30.6%. Results were consistent in patients with and without OAS (−33.6% and −28.4%, respectively).
A significant reduction in LS mean AAdSS was also observed over the first pollen season. The most frequently
reported adverse events were application site reactions: oral pruritus, throat irritation, and mouth edema. There
were no reports of anaphylaxis.
Conclusions: Pre- and co-seasonal treatment with 300IR birch pollen sublingual solution demonstrated sustained
clinical efficacy over 2 pollen seasons and was well tolerated in adults with birch pollen-associated allergic
rhinoconjunctivitis. Efficacy results were consistent in patients with and without oral allergy syndrome.
Trial registration: ClinicalTrials.gov: NCT01731249.
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Birch is common in Northern Europe and is considered
the major pollen-allergen-producing tree in Northern
Europe. The pollen is generally present from March to
May, depending on the latitude, and for up to 8 weeks
[1]. Sensitization to birch correlates with the distribution
of the tree, with low prevalence in Southern Europe and
high prevalence in Northern Europe [2]. Cross-reactivity
to alder and hazel contributes to a prolonged tree pollen
season in patients with birch pollen allergy [3]. In addition
to allergic rhinoconjunctivitis (ARC) symptoms, 50% to
93% of birch pollen allergic patients develop an oral al-
lergy syndrome (OAS), with oropharyngeal symptoms
after eating certain foods, because of the cross-reactivity
between the major birch pollen allergen, Bet v 1, and the
food proteins [4-6].
ARC represents a considerable burden on public health
because of its prevalence, its impact on quality of life and
productivity, its economic costs, and its associated co-
morbidities, including asthma [7-9]. Current treatment
options for ARC are allergen avoidance, symptomatic
pharmacotherapy, and allergen immunotherapy (AIT).
Limiting exposure to outdoor triggers is quite difficult for
practical reasons. Symptomatic treatment options include
antihistamines, intranasal corticosteroids, and leukotriene
modifiers. These provide temporary relief from allergy
symptoms but are not effective in all patients and are not
disease-modifying [7]. WAO Guidelines recommend AIT
by subcutaneous (SCIT) or sublingual (SLIT) route as
therapeutic options for patients whose symptoms are not
adequately controlled by avoidance measures or medica-
tions, those experiencing unacceptable adverse effects of
medications, or those who wish to reduce the long-term
use of medications [10,11].
The positive benefit-risk ratio of SLIT and its ease of
use are likely factors that have contributed to its sub-
stantially increased use in Europe [10,12]. However, as
there have been few large, double-blind, controlled AIT
trials for birch [12,13], this study was conducted to as-
sess the sustained efficacy (over two pollen seasons) and
safety of pre- and co-seasonal treatment with 300IR
(Index of Reactivity) birch-pollen sublingual solution in
adults with birch-pollen induced ARC. The study also
explored the efficacy and safety of treatment with the
birch-pollen sublingual solution in the subpopulations
with and without oral allergy syndrome.
Methods
Trial design
This was a randomized, double-blind, placebo-controlled
study conducted at 56 study centers in 11 European
countries (ClinicalTrials.gov number: NCT01731249).
Patients were enrolled between November 2010 and
January 2011 for a two-year study consisting of two pre-and co-seasonal treatment periods in 2011 and 2012
(Figure 1).
Eligible patients were randomized 1:1 by center (block
size of 4) using a computer-generated list to receive pla-
cebo or 300IR sublingual solution of birch pollen aller-
gen extract initiated approximately 4 months before the
expected start of the birch pollen season and continued
throughout the season. Randomization was stratified ac-
cording to the presence or absence of OAS and with the
objective of enrolling a similar number of patients with
and without OAS. Patients, investigators and all other
study personnel remained blinded for the entire study.
The study complied with ICH good clinical practice and
was approved by local Regulatory Authorities and Inde-
pendent Ethics Committees. Patients gave their written
informed consent before performance of any study-
related procedure. For a list of ethics committees which
provided approval for this study, please see Additional
file 1.Patients
The study enrolled men and women aged 18 to 65 with
documented birch pollen-related ARC for at least the
two previous birch pollen seasons that required intake of
symptomatic treatments. Sensitivity to birch pollen was
verified by a positive Skin Prick Test (Stallergenes S.A.),
defined as wheal diameter > 3 mm, birch-specific serum
IgE (ImmunoCAP, Thermoscientific) ≥ 0.70 kUA/L, and
a Retrospective Rhinoconjunctivitis Total Symptom
Score (RRTSS) ≥ 12 (0–18 scale) based on the most se-
vere days during one of the two birch pollen seasons
preceding enrolment. Patients were excluded from the
study if they had symptoms of rhinitis/rhinoconjunctivitis
during the birch pollen season due to any other allergen
(except alder and hazel), had received AIT treatment to
birch pollen and/or another Betulaceae species (such as
hazel or alder) within the previous 5 years, were receiving
AIT for any other allergen, or had moderate or severe per-
sistent asthma. Patients with asthma controlled with in-
haled corticosteroids at a maximum dose of 400 μg of
budesonide or the equivalent were eligible.Study treatment and rescue medications
Active treatment consisted of a sublingual solution of
birch-pollen allergen standardized extract (Staloral,
Stallergenes S.A., Antony, France) provided at a con-
centration of 10IR/mL for the titration phase and
300IR/mL for both the titration and maintenance
phases. IR is the in-house standardization unit used to
quantify the allergenicity of a solution. The titer of an
allergen extract solution corresponds to 100IR/mL
when, in an SPT performed with the Stallergenes’ SPT
device (Stallerpoint®), in 30 subjects sensitized to the
Birch pollen 
















Figure 1 Study design. The no-treatment period was about 7 months.
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measuring 7 mm in diameter (geometric mean).
Each year, treatment was initiated with a 12-day titra-
tion phase during which the dose was progressively in-
creased daily from 1IR to 300IR. The dose regimen was
as follows: 1, 2, 4, 6, 8, 10, 30, 60, 120, 180, 240, and
300IR/day. The maintenance phase consisted of daily in-
take of a 300IR dose until the end of the birch pollen
season. Patients were instructed to deposit the pre-
scribed dose directly under the tongue and keep it there
for 2 minutes before swallowing. Each year, the first dose
of treatment was taken at the study site and the patients
were monitored for 30 minutes; the remainder of the
treatment was taken at home. To maintain blinding, the
placebo sublingual solution was matched in appearance,
color and taste (i.e., the same glycerol saline solution was
used and a coloring agent added for color matching).
Rescue medications (oral and ophthalmic antihista-
mines and nasal corticosteroids) were provided to pa-
tients to be used according to a stepwise regimen to
manage severe ARC symptoms due to birch pollen. The
investigator could provide oral corticosteroids if other
rescue medications were insufficient.
Assessments
At the beginning of each treatment period, patients re-
ceived an electronic diary (PHT Corporation, Geneva,
Switzerland) and were advised to record, on a daily
basis, their intake of the investigational product, the se-
verity of each of their six rhinoconjunctivitis symptoms
(sneezing, rhinorrhea, nasal pruritus, nasal congestion,
ocular pruritus and watery eyes) on a 4-point descriptor
scale from 0 (absent) to 3 (severe) and their use of res-
cue medication during the previous 24 hours.
Each study year, the patients completed the standard-
ized Rhinoconjunctivitis Quality of Life Questionnaire
(RQLQ[S])[14] before the first intake of the investiga-
tional product (i.e., 4 months before the expected start
of the birch pollen period), then every week from 2 weeks
before the expected start of the birch pollen season to
2 weeks after its end (i.e., end of the treatment period).Birch-specific serum IgE and IgG4 were measured
using fluoroenzyme immunoassay at study entry, about
2 weeks after the end of the first pollen season, about
4 months before the second pollen period and about
2 weeks after the end of the second pollen season
(ImmunoCAP, Thermoscientific).
Safety variables were adverse events (AEs) monitored
from the signing of patient informed consent as well as
data from physical examinations and clinical laboratory
assessments. For each treatment period, treatment-
emergent adverse events (TEAEs) were defined as adverse
events which started on or after the first administration of
the investigational product, up to 30 days after its last
intake.
Outcomes
The sum of the six Rhinoconjunctivitis Symptom Scores
(RSS) defined the daily Rhinoconjunctivitis Total Symp-
tom Score (RTSS, range 0–18). The daily Rescue Medi-
cation Score (RMS) was derived as follows: 0 = no rescue
medication taken; 1 = use of antihistamines (oral and/or
ophthalmic); 2 = use of nasal corticosteroids; 3 = use of
oral corticosteroids. If more than one class of rescue
medication was taken on a particular day, the highest
score was retained for the score of that day.
The primary efficacy variable was the Average Adjusted
Symptom Score (AAdSS, range 0–18) during the second
birch pollen period. The AAdSS takes into account both
symptom scores and rescue medication usage. It is sub-
ject specific and is calculated as the average of the daily
Adjusted Symptom Scores (AdSSs) over the evaluation
period. Each day, the AdSS adjusts the daily RTSS for
rescue medication usage. If a patient took rescue medi-
cation on one day, the AdSS of that day is defined as
the RTSS of that day or the AdSS of the day before,
whichever was higher. The next day, the AdSS is de-
fined as the RTSS of that day or the AdSS of the day
before, whichever was higher [15]. Secondary efficacy
variables included the Average RTSS (ARTSS), individ-
ual Average RSSs (ARSSs), Average RMS (ARMS), and
overall RQLQ(S) score.
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The estimated site-specific start and end dates of the
2011 and 2012 birch pollen seasons were supplied by
SciCon Pharma Sciences (Vienna, Austria) taking into
account historical pollen data and seasons for the vari-
ous sites. Actual daily pollen counts and pollen graphs
of the 2011 and 2012 birch pollen seasons were provided
so that the start and end of the pollen seasons at each
site were defined before data unblinding. The birch-
pollen period at each site was defined as the period cov-
ering 90% of the total annual birch-pollen count.
Statistical analyses
Based on previous birch pollen studies, given an α = 0.05
and a coefficient of variation of the primary endpoint of












Discontinued n = 30 
Adverse event 14 
Consent withdrawn 8 
Lack of compliance 3 
Investigator Request 1 
Pregnancy 1 









(85.6% of randomized 
patients)
Discontinued n = 10
Adverse event 3 
Consent withdrawn 3 
Lack of compliance 3 
Other reason 1
Figure 2 Patient disposition. Patients were randomized to receive either p
approximately 4 months before the birch pollen season and continued throuper treatment group would provide 90% power to detect
at least a 20% relative mean difference vs. placebo, which
is the threshold recommended by the WAO taskforce as
clinically relevant for efficacy [16,17]. Assuming a drop-
out rate of 12% per year, it was planned to randomize
544 patients (i.e., 272 per treatment group).
Statistical analyses were performed using the SAS
System® for Windows version 9.1 or higher (SAS Institute,
Cary, North Carolina, USA). The threshold for statistical
significance was set at p < 0.05 and all inferential tests
were 2-sided.
The Full Analysis Sets for Period 1 (FASP1) and Period
2 (FASP2) included all patients who received at least one
dose of the investigational product during that period






















N = 253 
(87.2% of randomized 
patients)
Discontinued n = 9
Adverse event 3 
Consent withdrawn 2 
Lack of efficacy 1 
Pregnancy 2 
Other reason 1 
Discontinued n = 27
Adverse event 9 
Consent withdrawn 7
Lack of compliance 5
Lost to follow-up 1 
Lack of efficacy 1 
Pregnancy 1 
Other reason 3
lacebo or 300IR sublingual solution of birch allergen extract initiated
gh it. Patients were treated discontinuously for two consecutive years.
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second birch pollen period for the FASP2) was ana-
lyzed using an analysis of covariance (ANCOVA) with
treatment as main effect, OAS status and pooled
centre as stratification variables, and age in categor-
ies, gender, asthma status and baseline sensitization
status as covariates. The primary efficacy analysis was
repeated on the subgroups of patients with and with-
out OAS. ARTSS, ARMS, and ARSSs were analyzed
as per the primary efficacy criterion. The RQLQ(S)
was analyzed using a linear mixed effects model with
the weekly overall RQLQ(S) scores during the birch
pollen period as dependent variables and treatment
group, week number, baseline RQLQ(S) overall score,
pooled centre, OAS status, age, gender, asthma and
sensitization status as independent variables. The
same analyses were repeated for the first pollen




N = 261 N = 275
Age (years) 36.6 (11.26) 38.6 (10.97)
Gender (n and % female) 137 (52.5) 141 (51.3)
Duration of allergic rhinoconjunctivitis
(years)
13.7 (10.72) 14.2 (10.52)
Presence of Oral Allergy Syndrome (n, %) 141 (54.0) 150 (54.5)
FEV1 (% predicted) 100.7 (11.82) 101.8 (13.80)
RRTSS 14.2 (1.62) 14.4 (1.75)
Presence of asthma (n, %) 75 (28.7) 58 (21.1)
Poly-sensitized* (n, %) 179 (68.6) 205 (74.5)
PERIOD 2
Placebo 300IR
N = 247 N = 253
Age (years) 36.7 (11.33) 38.4 (11.05)
Gender (n and % female) 129 (52.2) 132 (52.2)
Duration of allergic rhinoconjunctivitis
(years)
13.4 (10.39) 13.8 (10.49)
Presence of Oral Allergy Syndrome (n, %) 133 (53.8) 138 (54.5)
FEV1 (% predicted) 100.8 (12.05) 102.1 (13.58)
RRTSS 14.2 (1.60) 14.4 (1.75)
Presence of asthma (n, %) 70 (28.3) 54 (21.3)
Poly-sensitized* (n, %) 169 (68.4) 185 (73.1)
Results describing continuous variables are expressed as means (SDs). Results
describing categorical variables are expressed as the number of patients and
the percentage relative to the number of patients in the FASP1 and FASP2 with
non-missing data.
RRTSS = Retrospective Rhinoconjunctivitis Total Symptom Score.
*Sensitized to birch pollen and at least one other allergen tested.Results
A total of 574 patients were randomized and 572 re-
ceived at least one dose of the investigational product:
283 in the 300IR group and 289 in the placebo group.
Of these, 253 patients in the 300IR group and 262 pa-
tients in the placebo group completed the first period
and started the second period of treatment. A total of
496 patients completed the study (Figure 2).
Demographics and baseline characteristics were simi-
lar in the two groups at study entry and remained so at
the start of the second study year (Table 1). At study
entry, the average patient had a history of birch-
associated allergic rhinitis for about 14 years, more than
68% were polysensitized, 20% had asthma, and about
54% had OAS.
As treatment was initiated 4 months before the pollen
season and continued for its duration, there could be





























































Period 1 Period 2
Figure 3 Average Adjusted Symptom Score. Data are presented
for the overall population and by baseline OAS status during Periods
1 (A) and 2 (B, Primary Endpoint) in the FASP1 and FASP2. ANCOVA
*p < 0.05; **p < 0.001; ***p < 0.0001.
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were treated for approximately 5 months in each of the
2 years of the study. The mean treatment duration was
146 days for the 300IR group and 145 days for the pla-
cebo group in Period 1, and 168 days and 169 days, re-
spectively in Period 2.Efficacy outcomes
During the second birch pollen period, the AAdSS,
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Figure 4 Daily mean Adjusted Symptom Score and birch pollen seaso
FASP2. The daily mean birch pollen count (grains/m
3) was the average of p
area of each pollen trap.medication, was significantly lower in the 300IR group
compared to placebo (Figure 3B) with a difference in LS
means of −2.04 (95% CI [−2.69; −1.40], p < 0.0001), cor-
responding to a relative LS means difference of −30.6%.
Over the first pollen period, the difference was −1.42
(95% CI [−2.07; −0.77], p < 0.0001). This corresponds to
a relative LS means difference of −19.0%.
The same analyses performed in the subgroups of pa-
tients with and without OAS showed statistically signifi-
cant differences in AAdSS compared to placebo for both
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n. Data are presented for Periods 1 (A) and 2 (B) in the FASP1 and
ollen count weighted by the number of patients within the catchment
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with OAS were observed during the second pollen
period.
Throughout each pollen period, the mean daily AdSSs
increased with the pollen exposure at each catchment
area and the daily AdSSs of the placebo group were al-
ways higher than those of the 300IR group (Figure 4).
During both pollen periods, the use of rescue medication
as reflected by the ARMS was significantly reduced in the
300IR group compared to the placebo group (p < 0.0001),
with relative LS mean differences of −29.3% and −41.9%,
respectively (Figure 5A). During the second pollen period,
this resulted in a significant reduction (p < 0.0001) in the
proportion of patients who used at least one rescue medi-
cation in the 300IR group (60.7%) compared to the placebo
group (81.8%). For each class of rescue medication, the
proportion of days rescue medications were used was
higher in the placebo group.
When considering symptoms alone, there was a sta-
tistically significant difference in ARTSS compared to





















































































































Figure 5 Symptoms and medication scores. Average Rescue Medication
Average Rhinoconjunctivitis Symptom Scores (C) for Periods 1 and 2 in thewith a corresponding LS means difference of −28.0%.
Similar results were observed during the first pollen
period (Figure 5B). Each of the six ARSSs were lower in
the 300IR group compared to placebo during both pollen
periods, with corresponding relative LS means differences
ranging from −10.1% to −19.4% during the first pollen
period and from −19.6% to −34.0% during the second
pollen period (Figure 5C), and statistically significant dif-
ferences for all symptom scores during the second pollen
period. For both pollen periods, the largest reduction in
symptom severity in the active treatment group compared
to placebo was observed for ocular pruritus.
Each pollen period, a significant difference between
the 300IR and placebo groups was shown for the overall
RQLQ(S) scores. During the first pollen period, the over-
all RQLQ(S) LS mean difference was −0.44 (95% CI
[−0.74; −0.15]) compared to placebo, corresponding to a
relative LS means difference of −23.1%. During pollen
period 2, the RQLQ(S) LS mean difference was of −0.55
(95% CI [−0.85; −0.24]) compared to placebo, correspond-











































































































Score (A), Average Rhinoconjunctivitis Total Symptom Score (B) and


































Period 1 Period 2
Placebo Placebo300IR 300IR
Period 1 Period 2
Figure 6 Standardized Rhinoconjunctivitis Quality of Life
Questionnaire (RQLQ[S]) overall scores. Data are presented for
birch pollen Periods 1 and 2 in the FASP1 and FASP2. Linear mixed




























































End of pollen 
period
Period 1 Period 2
Period 1 Period 2
Figure 7 Immunological markers (FASP1, FASP2). Serum specific-
IgG4 levels (A) and serum specific-IgE levels (B) at baseline, at the
end of pollen period (Period 1), 4 months before the pollen period
(Period 2) and at the end of the pollen period (Period 2).
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At study entry, birch-specific serum IgE and IgG4 were
similar in the 300IR and placebo groups. At the end of the
second pollen period, the change from baseline in birch-
specific serum IgE was similar in the two treatment
groups, however, birch-specific serum IgG4 increased by
about four-fold in the 300IR group but was essentially un-
changed in the placebo group (Figure 7).
Safety
For each study period, the safety set included all patients
who received at least one dose of the investigational
product: 572 patients in Period 1 and 511 in Period 2.
There were no deaths during the study and no reports
of anaphylaxis. Ten patients reported serious TEAEs
during Period 1: 8 in the active group (pneumonia, ery-
sipelas, abscess of external auditory meatus, syncope,
colitis, urticaria, hemorrhagic stroke, and pancreatitis)
and 2 in the placebo group (bronchopneumonia and
pulmonary malformation). Among them, urticaria was
the only event considered related to treatment by the in-
vestigator. During the second Period, 5 patients reported
serious TEAEs: 2 in the active group (sciatica and meta-
static colon cancer) and 3 in the placebo group (hemipar-
esis, peritoneal adhesions and subarachnoid hemorrhage);
none were considered drug-related.
A similar percentage of patients reported TEAEs in the
2 groups: 70.7% in the active group and 64.0% in theplacebo group. The most frequent TEAEs were applica-
tion site reactions: oral pruritus, mouth edema and throat
irritation (Table 2). During Period 2, 46.8% in the active
group and 48.6% in the placebo group reported TEAEs,
the most frequent being oral pruritus. As sublingual im-
munotherapy entails direct exposure of the oral mucosa
to the allergen responsible for the OAS, the safety profile
was also considered in the subgroups of patients with and
without OAS. During Period 1, the incidence of TEAEs in
patients with OAS was similar in the two treatment
groups (78.3% in the active group and 73.4% in the pla-
cebo group) and was higher than in patients without OAS
(61.8% in the active group and 52.7% in the placebo
group). This was also observed during Period 2.
A total of 22 patients withdrew due to TEAEs during
Period 1: 13 in the active group (including 9 with OAS)
Table 2 Incidence of TEAEs reported by at least 5% of participants in either treatment group
System organ class
Preferred term
Overall population With OAS Without OAS
300IR Placebo 300IR Placebo 300IR Placebo
(N = 283) (N = 289) (N = 152) (N = 158) (N = 131) (N = 131)
n (%) n (%) n (%) n (%) n (%) n (%)
PERIOD 1
Patients who had at least one TEAE 200 (70.7) 185 (64.0) 119 (78.3) 116 (73.4) 81 (61.8) 69 (52.7)
Gastrointestinal disorders 126 (44.5) 54 (18.7) 83 (54.6) 36 (22.8) 43 (32.8) 18 (13.7)
Oral pruritus 70 (24.7) 11 (3.8) 47 (30.9) 7 (4.4) 23 (17.6) 4 (3.1)
Edema mouth 28 (9.9) 0 (0.0) 21 (13.8) 0 (0.0) 7 (5.3) 0 (0.0)
Infections and infestations 89 (31.4) 106 (36.7) 57 (37.5) 71 (44.9) 32 (24.4) 35 (26.7)
Nasopharyngitis 31 (11.0) 43 (14.9) 23 (15.1) 26 (16.5) 8 (6.1) 17 (13.0)
Respiratory, thoracic, mediastinal disorders 64 (22.6) 43 (14.9) 42 (27.6) 30 (19.0) 22 (16.8) 13 (9.9)
Throat irritation 19 (6.7) 2 (0.7) 14 (9.2) 2 (1.3) 5 (3.8) 0 (0.0)
Nervous system disorders 53 (18.7) 53 (18.3) 38 (25.0) 37 (23.4) 15 (11.5) 16 (12.2)
Headache 49 (17.3) 44 (15.2) 34 (22.4) 31 (19.6) 15 (11.5) 13 (9.9)
Musculoskeletal and connective tissue disorders 25 (8.8) 27 (9.3) 17 (11.2) 15 (9.5) 8 (6.1) 12 (9.2)
Eye disorders 22 (7.8) 27 (9.3) 17 (11.2) 17 (10.8) 5 (3.8) 10 (7.6)
Skin and subcutaneous tissue disorders 13 (4.6) 17 (5.9) 7 (4.6) 15 (9.5) 6 (4.6) 2 (1.5)
PERIOD 2
300IR Placebo 300IR Placebo 300IR Placebo
(N = 252) (N = 259) (N = 134) (N = 142) (N = 118) (N = 117)
n (%) n (%) n (%) n (%) n (%) n (%)
Patients who had TEAE 118 (46.8) 126 (48.6) 68 (50.7) 80 (56.3) 50 (42.2) 46 (39.3)
Infections and infestations 65 (25.8) 77 (29.7) 41 (30.6) 50 (35.2) 24 (20.3) 27 (23.1)
Nasopharyngitis 19 (7.5) 34 (13.1) 12 (9.0) 22 (15.5) 7 (5.9) 12 (10.3)
Gastrointestinal disorders 41 (16.3) 23 (8.9) 27 (20.1) 15 (10.6) 14 (11.9) 8 (6.8)
Oral pruritus 21 (8.3) 2 (0.8) 14 (10.4) 2 (1.4) 7 (5.9) 0 (0)
Nervous system disorders 17 (6.7) 21 (8.1) 11 (8.2) 19 (13.4) 6 (5.1) 2 (1.7)
Headache 13 (5.2) 17 (6.6) 10 (7.5) 16 (11.3) 3 (2.5) 1 (0.9)
Respiratory, thoracic, mediastinal disorders 14 (5.6) 21 (8.1) 10 (7.5) 14 (9.9) 4 (3.4) 7 (6.0)
Musculoskeletal and connective tissue disorders 14 (5.6) 18 (6.9) 7 (5.2) 12 (8.5) 7 (5.9) 6 (5.1)
Safety SetP1, Safety SetP2. Adverse events were classified according to their system organ class and preferred term (MedDRA version 14.0).
TEAEs were adverse events occurring during the treatment period up to 30 days after the last treatment administration.
n = number of patients with at least one event in given preferred term; % = percentage of patients with at least one event relative to the number of patients in
each treatment group (N) in the Safety Sets.
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these, the most common TEAEs were local reactions and
were considered related to the treatment. During the sec-
ond treatment period, 5 patients (3 in the active group and
2 in the placebo group) withdrew due to TEAEs.Discussion
Earlier birch pollen AIT studies have shown positive out-
comes [18-21], but have either included small numbers
of patients [18-20] or were observational [21,22]. The
need for larger scale studies of sublingual immunother-
apy has long been acknowledged [17].The present study is the largest to date specifically fo-
cused on assessing the efficacy and safety of a sublingual
solution of birch pollen allergen extract as treatment for
allergic rhinitis. After two consecutive pre- and co-
seasonal treatment periods, a significant, sustained reduc-
tion in symptoms and medication use, measured with the
Average Adjusted Symptom Score, was demonstrated for
the 300IR dose. The robustness of this finding was sup-
ported by the positive results on secondary endpoints in-
cluding efficacy during the first birch pollen period.
Evaluation of treatment efficacy included the assess-
ment of patient self-reported quality of life. Each pollen
period, a significant difference in RQLQ(S) overall score
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the second pollen period, the adjusted mean difference
vs. placebo was greater than 0.5, the intra-patient min-
imal clinically important difference defined for symp-
tomatic treatments [23]. Of note, in this study rescue
medication was permitted as treatment for severe rhino-
conjunctivitis symptoms and was used more frequently
in the placebo group. Therefore, the true impact of treat-
ment with the sublingual solution of birch pollen aller-
gen extract on patients’ quality of life as evaluated by the
RQLQ was underestimated.
Randomization was stratified on the presence or ab-
sence of OAS. Efficacy of the birch-pollen sublingual solu-
tion was similar in the subgroups with and without OAS,
with statistically significant reductions in overall symptom
scores (i.e., AAdSS) and in the use of rescue medication,
compared to placebo, regardless of OAS status.
As shown in Figure 4, the pollen count was notably
higher during the second pollen season, (peak nearly
2400 grains/m3/24 h), compared to the first pollen sea-
son (peak at about 1000 grains/m3/24 h). In spite of the
higher pollen exposure, the relative adjusted mean differ-
ence in AAdSS in the active group relative to the pla-
cebo group was higher during the second pollen period
compared to the first pollen period.
In this study, birch pollen allergen extract sublingual so-
lution was associated with an acceptable safety profile.
There were no reports of anaphylaxis or serious severe lar-
yngopharyngeal reactions. The most frequent adverse
events were application site reactions (e.g., oral pruritus
and throat irritation). Consistent with the published ex-
perience with grass pollen sublingual immunotherapy, the
incidence of withdrawals due to adverse events decreased
from the first treatment period to the second [24,25].
The sustained clinical efficacy over 2 years, favorable
safety profile, and ability to administer birch pollen sub-
lingual immunotherapy at home, make this treatment an
alternative to subcutaneous immunotherapy for patients
with birch pollen-associated ARC.
Conclusions
In this European study, 4 months of pre-seasonal and
co-seasonal treatment with 300IR sublingual solution of
birch-pollen extract over 2 consecutive years demon-
strated sustained and clinically meaningful efficacy and
acceptable safety profile in adults with birch pollen-
associated allergic rhinoconjunctivitis. Efficacy and safety
were shown in the subpopulations of patients with and
without oral allergy syndrome.Additional file
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